分析师对 Lineage Cell Therapeutics, Inc.（NYSEAMERICAN:LCTX）2024 财年收益的预期

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - Research analysts at Cantor Fitzgerald lifted their FY2024 earnings estimates for shares of Lineage Cell Therapeutics in a research report issued on Monday, August 12th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will earn ($0.18) per share for the year, up from their previous estimate of ($0.20). The consensus estimate for Lineage Cell Therapeutics' current full-year earnings is ($0.12) per share.

Separately, HC Wainwright restated a "buy" rating and set a $7.00 target price on shares of Lineage Cell Therapeutics in a research report on Monday, May 6th.

View Our Latest Report on Lineage Cell Therapeutics

Lineage Cell Therapeutics Stock Down 1.3 %

Lineage Cell Therapeutics stock opened at $0.83 on Wednesday. Lineage Cell Therapeutics has a 52-week low of $0.82 and a 52-week high of $1.61. The stock has a market cap of $156.59 million, a price-to-earnings ratio of -5.92 and a beta of 1.29.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.01. The company had revenue of $1.41 million for the quarter, compared to analysts' expectations of $1.28 million. Lineage Cell Therapeutics had a negative net margin of 295.59% and a negative return on equity of 34.92%.

Institutional Trading of Lineage Cell Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. XTX Topco Ltd purchased a new stake in Lineage Cell Therapeutics in the 2nd quarter worth $61,000. Renaissance Technologies LLC grew its position in shares of Lineage Cell Therapeutics by 10.0% during the second quarter. Renaissance Technologies LLC now owns 583,622 shares of the company's stock worth $582,000 after purchasing an additional 53,022 shares in the last quarter. Rhumbline Advisers raised its stake in Lineage Cell Therapeutics by 15.1% during the 2nd quarter. Rhumbline Advisers now owns 132,491 shares of the company's stock valued at $132,000 after purchasing an additional 17,411 shares during the period. Bank of New York Mellon Corp lifted its holdings in Lineage Cell Therapeutics by 35.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 435,958 shares of the company's stock worth $435,000 after purchasing an additional 114,762 shares in the last quarter. Finally, Comerica Bank boosted its stake in Lineage Cell Therapeutics by 84,745.8% in the 1st quarter. Comerica Bank now owns 250,295 shares of the company's stock worth $370,000 after purchasing an additional 250,000 shares during the period. 62.47% of the stock is currently owned by institutional investors.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

See Also

• Five stocks we like better than Lineage Cell Therapeutics
• How to Invest in the Best Canadian Stocks
• Instacart Stock Gains Momentum with Profits and AI-Powered Carts
• Basic Materials Stocks Investing
• Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?
• Stock Sentiment Analysis: How it Works
• Top 3 Dividend-Paying Stocks for Stability in Volatile Markets

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ This One stock is all you need... (From Behind the Markets) (Ad)

Should you invest $1,000 in Lineage Cell Therapeutics right now?

Before you consider Lineage Cell Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lineage Cell Therapeutics wasn't on the list.

While Lineage Cell Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here